84
Participants
Start Date
August 31, 2015
Primary Completion Date
December 31, 2023
Study Completion Date
August 31, 2025
Nivolumab
nivolumab 3 mg/kg, every 2 weeks after induction treatment
Radiation therapy
20 Gy to metastatic lesion
Low dose doxorubicin
15 mg flat dose, once weekly for 2 weeks
Cyclophosphamide
metronomic schedule, 50 mg daily orally for 2 weeks
Cisplatin
40 mg/m2, weekly for 2 weeks
Antoni van Leeuwenhoek, Amsterdam
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
The Netherlands Cancer Institute
OTHER